Abstract
In late December, FDA approved teduglutide (Gattex—NPS) to treat short bowel syndrome in adult patients who need additional nutrition from I.V. parenteral nutrition. The drug is a glucagon-like peptide-2 (GLP-2) analog that improves intestinal absorption of fluids and nutrients, thereby reducing the frequency and volume of parenteral nutrition. Teduglutide is only the third drug approved to treat adults with short bowel syndrome receiving nutritional support.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
